- Genmab Announces Financial Results for the First Quarter of 2024
- TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer
- Transactions in Connection with Share Buy-back Program Genmab
- Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2024
- Transactions in Connection with Share Buy-back Program
- Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio
- Completion of share buy-back program
- Genmab Announces Initiation of Share Buy-Back Program
- Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
- Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab
More ▼
Key statistics
On Thursday, Genmab A/S (GMAB:CPH) closed at 1,946.00, 6.63% above its 52-week low of 1,825.00, set on Feb 13, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1,986.50 |
---|---|
High | 2,002.00 |
Low | 1,938.50 |
Bid | 1,946.00 |
Offer | 1,946.00 |
Previous close | 1,965.50 |
Average volume | 119.27k |
---|---|
Shares outstanding | 66.12m |
Free float | 66.12m |
P/E (TTM) | 29.86 |
Market cap | 130.39bn DKK |
EPS (TTM) | 66.05 DKK |
Data delayed at least 15 minutes, as of May 02 2024 16:10 BST.
More ▼